Job title: Postdoctoral Training Fellow
Location: The Francis Crick Institute, Midland Road, London
Contract: Fixed-term, 4 years
Salary: Competitive with benefits, subject to skills and experience
Vacancy ID: 10390
An exciting opportunity to be part of a pioneering biomedical research institute, dedicated to innovation and science. A postdoctoral research post in the laboratory of Immunity and Cancer headed by Dinis Calado funded by LEUKA and The Francis Crick Institute is now available. We are looking for a highly motivated researcher to use mouse models to study lymphoma clonal evolution. This research builds upon work aiming to identify underlying molecular mechanisms of resistance or relapse to standard treatment. The successful applicant will use a wide range of techniques including mouse genetics, flow-cytometry, Cytof, RNA and Exome sequencing. This project will be performed in close collaboration with Jude Fitzgibbon at the Centre of haemato-oncology Barts Cancer Institute, expert in human lymphoma genetics. The successful applicant will have excellent communication and organisational skills, a PhD in immunology, cancer or a relevant area (or be in the final stages of completion).
A significant proportion (40%) of lymphoma patients have refractory disease or relapse to the first line immuno-chemotherapy ultimately succumbing to the disease. Lymphomas with over-expression of MYC have poorer prognosis. However, progress in understanding the underlying molecular mechanisms of resistance or relapse has been slow. This project will validate state of the art genetically engineered mouse model systems for longitudinal clonal evolution analysis of various lymphoma sub-types carrying MYC overexpression. In these systems the aim is to perform direct comparisons of lymphoma and microenvironment cells in a pre- and post-treatment scenario, of the same tumour occurring in the same mouse using surgical procedures. These initial studies will guide the development and testing of novel therapeutic regimes including the informed usage of immune-checkpoint blockade. The overall aim of the project is to investigate the feasibility of mouse model systems in prognosticating human disease relapse and refractoriness to standard treatment and to inform medical decisions for treatment alternatives.
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.
The Crick was formed in 2015, and in 2016 it moved into a new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under in one building in Europe.
The Francis Crick Institute will be world-class with a strong national role. Its distinctive vision for excellence includes commitments to collaboration; developing emerging talent and exporting it the rest of the UK; public engagement; and helping turn discoveries into treatments as quickly as possible to improve lives and strengthen the economy.
• If you are interested in applying for this role, please apply via our website.
• The closing date for applications is 29 April 2019 at 23:30.
• All offers of employment are subject to successful security screening and continuous eligibility to work in the United Kingdom.